-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67

Benzinga·10/07/2026 14:56:22
Listen to the news
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $65 to $67.